posterpresentation
Description

Title: 0963 - Low-temperature Plasma on Peri-implant Related Biofilm and Gingival Tissue

Authors:

Adriana Carreiro (Presenter)
UFRN

Juliana Delben, Universidade Estadual do Paraná
Sarah Guedes, UFC
Ericka Silveira, UFRN
Malvin Janal, New York University
Carlos Eduardo Vergani, UNESP
Simone Duarte, New York University

Abstract:

Objectives: Evaluate the effect of LTP on an anaerobic biofilm and on the biological response of an in vitro reconstituted gingival epithelium tissue.

Methods: P.gingivalis W83 biofilm was cultured on titanium discs and reconstituted gingival tissue were submitted to similar treatment conditions. Treatments: LTP1 – plasma treatment for 1 min, LTP3 – plasma treatment for 3 min, CHX –0.2% chlorhexidine for 1 min, GAS – gas only (no plasma) for 3 min, NEGATIVE – no treatment. TRITON group (100mL of 1% triton X-100) was included as a positive control for tissue analysis. Counting of viable colonies (CFU/mL) and confocal laser scanning microscopy were performed to evaluate LTP’s antimicrobial effect. EpiGingivalTM tissue was evaluated through cytotoxocity test, viability test, histology and imunnohistochemistry (Ki67, VEGF-A and TUNEL expression).

Results: LTP1 and LTP3 presented significantly different CFU/mL reduction in comparison to the negative control (ρ < 0.001). Low cytotoxicity and high viability were observed in gingival epithelium of NEGATIVE, GAS, CHX and both LTP groups. The morphological analysis of gingival tissue revealed minor cell damage in the plasma groups (score 1). LTP1, LTP3, GAS and NEGATIVE groups exhibited less than 5% of basal layer positive cells. LTP1, LTP3, GAS and CHX groups were not positive for TUNEL assay. LTP1 and LTP3 showed the most positivity for VEGF.

Conclusions: LTP treatment can be considered an effective method for reducing P. gingivalis biofilm on implant surfaces being safe for the gingival epithelium. Furthermore, an induced repair was seeing when plasma treatment was performed.

Disclosure Statement:
The submitter must disclose the names of the organizations with which any author have a relationship, the nature of the relationship, and the clinical or research area involved. The following is submitted: NONE

Tags